Separately, Northland Securities reaffirmed a buy rating on shares of Motif Bio in a research report on Tuesday, August 14th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Motif Bio currently has a consensus rating of Buy and an average price target of GBX 107.20 ($1.40).
Shares of MTFB opened at GBX 28.74 ($0.38) on Thursday. Motif Bio has a fifty-two week low of GBX 23.50 ($0.31) and a fifty-two week high of GBX 51.75 ($0.68).
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Recommended Story: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.